Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease.

Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E.

Neurobiol Dis. 2019 Nov 9;134:104647. doi: 10.1016/j.nbd.2019.104647. [Epub ahead of print]

2.

Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells.

Qi W, Davidson BA, Nguyen M, Lindstrom T, Grey RJ, Burnett R, Aflaki E, Sidransky E, Westbroek W.

Biochem J. 2019 Jan 25;476(2):261-274. doi: 10.1042/BCJ20180708.

PMID:
30578288
3.

Frequency of HLA-B5, HLA-B51 and HLA-B27 in patients with idiopathic uveitis and Behçet's disease: a case-control study.

Shenavandeh S, Jahanshahi KA, Aflaki E, Tavassoli A.

Reumatologia. 2018;56(2):67-72. doi: 10.5114/reum.2018.75516. Epub 2018 May 9.

4.

Temperament and character in patients with systemic lupus erythematosus.

Mani A, Rostami A, Aflaki E, Ravanfar P.

Compr Psychiatry. 2018 Jan;80:104-108. doi: 10.1016/j.comppsych.2017.09.007. Epub 2017 Sep 19.

PMID:
29080410
5.

Induced pluripotent stem cell models of lysosomal storage disorders.

Borger DK, McMahon B, Roshan Lal T, Serra-Vinardell J, Aflaki E, Sidransky E.

Dis Model Mech. 2017 Jun 1;10(6):691-704. doi: 10.1242/dmm.029009. Review.

6.

Re: HLA is better than serological screening for celiac diseases in rheumatological arthritis.

Moghtaderi M, Farjadian S, Aflaki E, Honar N, Alyasin S, Babaei M.

Turk J Gastroenterol. 2017 May;28(3):228. doi: 10.5152/tjg.2017.2704021. No abstract available.

7.

Recalcitrant cases of pyoderma gangrenosum, responding dramatically to systemic tacrolimus.

Sadati MS, Dastgheib L, Aflaki E.

G Ital Dermatol Venereol. 2017 Jun;152(3):308-310. doi: 10.23736/S0392-0488.17.04876-3.

PMID:
28409579
8.

The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease.

Aflaki E, Westbroek W, Sidransky E.

Neuron. 2017 Feb 22;93(4):737-746. doi: 10.1016/j.neuron.2017.01.018. Review.

9.

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism.

McMahon B, Aflaki E, Sidransky E.

Neural Regen Res. 2016 Nov;11(11):1760-1761. doi: 10.4103/1673-5374.194717. No abstract available.

10.

Efferocytosis is impaired in Gaucher macrophages.

Aflaki E, Borger DK, Grey RJ, Kirby M, Anderson S, Lopez G, Sidransky E.

Haematologica. 2017 Apr;102(4):656-665. doi: 10.3324/haematol.2016.155093. Epub 2016 Dec 23.

11.

An elevated pro-inflammatory cytokines profile in Behcet's disease: A multiplex analysis.

Gholijani N, Ataollahi MR, Samiei A, Aflaki E, Shenavandeh S, Kamali-Sarvestani E.

Immunol Lett. 2017 Jun;186:46-51. doi: 10.1016/j.imlet.2016.12.001. Epub 2016 Dec 6.

PMID:
27939191
12.

Screening of patients with juvenile idiopathic arthritis and those with rheumatoid arthritis for celiac disease in southwestern Iran.

Moghtaderi M, Farjadian S, Aflaki E, Honar N, Alyasin S, Babaei M.

Turk J Gastroenterol. 2016 Nov;27(6):521-524. doi: 10.5152/tjg.2016.16354.

13.

A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.

Westbroek W, Nguyen M, Siebert M, Lindstrom T, Burnett RA, Aflaki E, Jung O, Tamargo R, Rodriguez-Gil JL, Acosta W, Hendrix A, Behre B, Tayebi N, Fujiwara H, Sidhu R, Renvoise B, Ginns EI, Dutra A, Pak E, Cramer C, Ory DS, Pavan WJ, Sidransky E.

Dis Model Mech. 2016 Jul 1;9(7):769-78. doi: 10.1242/dmm.024588. Epub 2016 May 19.

14.

A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.

Aflaki E, Borger DK, Moaven N, Stubblefield BK, Rogers SA, Patnaik S, Schoenen FJ, Westbroek W, Zheng W, Sullivan P, Fujiwara H, Sidhu R, Khaliq ZM, Lopez GJ, Goldstein DS, Ory DS, Marugan J, Sidransky E.

J Neurosci. 2016 Jul 13;36(28):7441-52. doi: 10.1523/JNEUROSCI.0636-16.2016.

15.

Applications of iPSC-derived models of Gaucher disease.

Borger DK, Aflaki E, Sidransky E.

Ann Transl Med. 2015 Nov;3(19):295. doi: 10.3978/j.issn.2305-5839.2015.10.41. No abstract available.

16.

Peganum Oil in Iranian Traditional Pharmacy.

Abolhassanzadeh Z, Aflaki E, Yousefi G, Mohagheghzadeh A.

Pharm Hist (Lond). 2015 Jun;45(2):34-6. No abstract available.

PMID:
26521618
17.

Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages.

Aflaki E, Moaven N, Borger DK, Lopez G, Westbroek W, Chae JJ, Marugan J, Patnaik S, Maniwang E, Gonzalez AN, Sidransky E.

Aging Cell. 2016 Feb;15(1):77-88. doi: 10.1111/acel.12409. Epub 2015 Oct 21.

18.

Active autophagy but not lipophagy in macrophages with defective lipolysis.

Goeritzer M, Vujic N, Schlager S, Chandak PG, Korbelius M, Gottschalk B, Leopold C, Obrowsky S, Rainer S, Doddapattar P, Aflaki E, Wegscheider M, Sachdev V, Graier WF, Kolb D, Radovic B, Kratky D.

Biochim Biophys Acta. 2015 Oct;1851(10):1304-1316. doi: 10.1016/j.bbalip.2015.06.005. Epub 2015 Jul 2.

19.

New macrophage models of Gaucher disease offer new tools for drug development.

Borger DK, Sidransky E, Aflaki E.

Macrophage (Houst). 2015;2(1):e712.

20.

Randomized clinical trial of peganum oil for knee osteoarthritis.

Abolhassanzadeh Z, Aflaki E, Yousefi G, Mohagheghzadeh A.

J Evid Based Complementary Altern Med. 2015 Apr;20(2):126-31. doi: 10.1177/2156587214566867. Epub 2015 Feb 4.

PMID:
25654976
21.

Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.

Aflaki E, Stubblefield BK, Maniwang E, Lopez G, Moaven N, Goldin E, Marugan J, Patnaik S, Dutra A, Southall N, Zheng W, Tayebi N, Sidransky E.

Sci Transl Med. 2014 Jun 11;6(240):240ra73. doi: 10.1126/scitranslmed.3008659.

22.

High prevalence of Helicobacter pylori infection in Behcet's disease.

Lankarani KB, Ravanbod MR, Aflaki E, Nazarinia MA, Rajaee A.

BMC Gastroenterol. 2014 Mar 31;14:58. doi: 10.1186/1471-230X-14-58.

23.
24.

Association of FCRL3 genotypes with susceptibility of Iranian patients to rheumatoid arthritis.

Golmoghaddam H, Amirghofran Z, Aflaki E, Kamali-Sarvestani E, Shabani M, Esmaeilbeig M, Rajabi M.

Immunol Invest. 2013;42(4):296-306. doi: 10.3109/08820139.2013.764314.

PMID:
23883198
25.

Anti-cardiolipin and anti-Neutrophil Cytoplasmic Antibodies in Iranian patients with Behcet's disease.

Ataollahi MR, Aflaki E, Nazarinia MA, Shenavandeh S, Habibagahi Z, Gharesi-Fard B, Kamali-Sarvestani E.

Iran J Immunol. 2012 Dec;9(4):241-7. doi: IJIv9i4A4.

26.

Toxicity of oxidized phospholipids in cultured macrophages.

Stemmer U, Dunai ZA, Koller D, Pürstinger G, Zenzmaier E, Deigner HP, Aflaki E, Kratky D, Hermetter A.

Lipids Health Dis. 2012 Sep 7;11:110. doi: 10.1186/1476-511X-11-110.

27.

Adipose triglyceride lipase in immune response, inflammation, and atherosclerosis.

Radovic B, Aflaki E, Kratky D.

Biol Chem. 2012 Sep;393(9):1005-11. doi: 10.1515/hsz-2012-0192. Review.

28.

Comparing the Effect of Phenytoin Syrup and Triamcinolone Acetonide Ointment on Aphthous Ulcers in Patients with Behcet's Syndrome.

Fani MM, Ebrahimi H, Pourshahidi S, Aflaki E, Shafiee Sarvestani S.

Iran Red Crescent Med J. 2012 Feb;14(2):75-8. Epub 2012 Feb 1.

29.

C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages.

Aflaki E, Doddapattar P, Radović B, Povoden S, Kolb D, Vujić N, Wegscheider M, Koefeler H, Hornemann T, Graier WF, Malli R, Madeo F, Kratky D.

Cell Death Dis. 2012 Mar 15;3:e280. doi: 10.1038/cddis.2012.17.

30.

Lack of acyl-CoA:diacylglycerol acyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice.

Chandak PG, Obrowsky S, Radovic B, Doddapattar P, Aflaki E, Kratzer A, Doshi LS, Povoden S, Ahammer H, Hoefler G, Levak-Frank S, Kratky D.

Biochim Biophys Acta. 2011 Dec;1811(12):1011-20. doi: 10.1016/j.bbalip.2011.08.010. Epub 2011 Sep 1.

31.

Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study.

Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR.

J Ren Nutr. 2012 Jan;22(1):50-7. doi: 10.1053/j.jrn.2011.03.002. Epub 2011 Jul 13.

PMID:
21742514
32.

Impaired Rho GTPase activation abrogates cell polarization and migration in macrophages with defective lipolysis.

Aflaki E, Balenga NA, Luschnig-Schratl P, Wolinski H, Povoden S, Chandak PG, Bogner-Strauss JG, Eder S, Konya V, Kohlwein SD, Heinemann A, Kratky D.

Cell Mol Life Sci. 2011 Dec;68(23):3933-47. doi: 10.1007/s00018-011-0688-4. Epub 2011 May 2. Erratum in: Cell Mol Life Sci. 2013 Jul;70(14):2621.

33.

GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils.

Balenga NA, Aflaki E, Kargl J, Platzer W, Schröder R, Blättermann S, Kostenis E, Brown AJ, Heinemann A, Waldhoer M.

Cell Res. 2011 Oct;21(10):1452-69. doi: 10.1038/cr.2011.60. Epub 2011 Apr 5. Erratum in: Cell Res. 2011 Nov;21(11):1641.

34.

Triacylglycerol accumulation activates the mitochondrial apoptosis pathway in macrophages.

Aflaki E, Radovic B, Chandak PG, Kolb D, Eisenberg T, Ring J, Fertschai I, Uellen A, Wolinski H, Kohlwein SD, Zechner R, Levak-Frank S, Sattler W, Graier WF, Malli R, Madeo F, Kratky D.

J Biol Chem. 2011 Mar 4;286(9):7418-28. doi: 10.1074/jbc.M110.175703. Epub 2011 Jan 1.

35.

Macrophage adipose triglyceride lipase deficiency attenuates atherosclerotic lesion development in low-density lipoprotein receptor knockout mice.

Lammers B, Chandak PG, Aflaki E, Van Puijvelde GH, Radovic B, Hildebrand RB, Meurs I, Out R, Kuiper J, Van Berkel TJ, Kolb D, Haemmerle G, Zechner R, Levak-Frank S, Van Eck M, Kratky D.

Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):67-73. doi: 10.1161/ATVBAHA.110.215814. Epub 2010 Oct 28.

36.

Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase.

Chandak PG, Radovic B, Aflaki E, Kolb D, Buchebner M, Fröhlich E, Magnes C, Sinner F, Haemmerle G, Zechner R, Tabas I, Levak-Frank S, Kratky D.

J Biol Chem. 2010 Jun 25;285(26):20192-201. doi: 10.1074/jbc.M110.107854. Epub 2010 Apr 27.

37.

Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus.

Godarzi EM, Sarvestani EK, Aflaki E, Amirghofran Z.

Clin Rheumatol. 2011 Feb;30(2):179-84. doi: 10.1007/s10067-010-1452-0. Epub 2010 Apr 11.

PMID:
20383729
38.

Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules.

Arasteh JM, Sarvestani EK, Aflaki E, Amirghofran Z.

Immunol Invest. 2010;39(1):27-38. doi: 10.3109/08820130903401736. Erratum in: Immunol Invest. 2010 Jan;39(3):292. Araste, Julia Maryam [corrected to Arasteh, Julia Maryam].

PMID:
20064083
39.

The relation between serum homocysteine level and eye involvement in Behçet's disease.

Aflaki E, Mehryar M, Nazarinia MA, Habibagahi Z, Rajaee A, Ranjbar-Omrani G.

Arch Iran Med. 2008 Nov;11(6):625-8.

40.

The prevalence and characteristics of different types of headache in patients with Behçet's disease, a case-control study.

Borhani Haghighi A, Aflaki E, Ketabchi L.

Headache. 2008 Mar;48(3):424-9. doi: 10.1111/j.1526-4610.2007.01041.x. Epub 2008 Jan 18.

PMID:
18205799
41.

Anticardiolipin and antibeta2glycoproteinI antibodies in patients with hepatitis B and C infections.

Habibagahi Z, Nazarinia MA, Aflaki E, Rajaee A.

Iran J Immunol. 2007 Sep;4(3):161-6.

42.

TNF-alpha, TNF-beta and IL-4 gene polymorphisms in Iranian patients with multiple sclerosis.

Kamali-Sarvestani E, Nikseresht A, Aflaki E, Sarvari J, Gharesi-Fard B.

Acta Neurol Scand. 2007 Mar;115(3):161-6.

PMID:
17295710

Supplemental Content

Loading ...
Support Center